2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-,(4S,4aS,5aS,6S,12aS)- cas no:127-33-3

Name2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-,(4S,4aS,5aS,6S,12aS)-
CAS127-33-3
Synonyms2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-(8CI); 2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-,[4S-(4a,4aa,5aa,6b,12aa)]-; 6-Demethyl-7-chlorotetracycline;6-Demethyl-7-chlortetracycline; 6-Demethylchlorotetracycline;6-Demethylchlortetracycline;7-Chloro-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide;7-Chloro-6-demethyltetracycline; Bioterciclin; Chlortetracycline, 6-demethyl-;DMCT; DMCT (antibiotic); Deganol; Demeclocycline; Demeclor;Demethylchlorotetracycline; Demethylchlortetracyclin;Demethylchlortetracycline; Demetraclin; Diuciclin; Elkamicina; Ledermycin;Mexocine; Novotriclina; Perciclina; Periciclina; RP 10192; Sumaclina;Tri-demethylchlortetracycline
EINECS(EC#)204-834-8
Molecular FormulaC21H21 Cl N2 O8
Molecular Weight464.89

Safety

Poison by intravenous and intraperitoneal routes. Human systemic effects by ingestion: diabetes insipidus, urine volume increase, other changes in urine composition, dermatitis, changes in the nails, allergic rhinitis, serum sickness, effects on cyclic nucleotides. Human reproductive effects by an unspecified route: postnatal measures or effects on newborn. An experimental teratogen. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of Cl⁻ and NO_x.

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
human	TDLo	oral	10mg/kg (10mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" SKIN AND APPENDAGES (SKIN): NAILS: OTHER	British Medical Journal. Vol. 2, Pg. 96, 1977.
human	TDLo	oral	68mg/kg/8D (68mg/kg)	KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION	Current Therapeutic Research, Clinical & Experimental. Vol. 15, Pg. 734, 1973.
human	TDLo	oral	420mg/kg/6W (420mg/kg)	ENDOCRINE: DIABETES INSIPIDUS (NEPHROGENIC OR CNS)	Annals of Internal Medicine. Vol. 79, Pg. 679, 1973.
mouse	LD50	intraperitoneal	454mg/kg (454mg/kg)		Drugs in Japan Vol. 6, Pg. 497, 1982.
mouse	LD50	intravenous	79mg/kg (79mg/kg)		Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 281, 1970.
mouse	LDLo	oral	4gm/kg (4000mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 129, Pg. 350, 1960.
mouse	LDLo	subcutaneous	2500mg/kg (2500mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 129, Pg. 350, 1960.
rat	LD50	intraperitoneal	358mg/kg (358mg/kg)		Drugs in Japan Vol. 6, Pg. 497, 1982.
rat	LD50	intravenous	146mg/kg (146mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 9, Pg. 759, 1967.
rat	LD50	oral	> 6750mg/kg (6750mg/kg)		Drugs in Japan Vol. 6, Pg. 497, 1982.
rat	LD50	subcutaneous	> 2gm/kg (2000mg/kg)		Drugs in Japan Vol. 6, Pg. 497, 1982.